Skip to main content
SCM Lifescience Co., Ltd. logo

SCM Lifescience Co., Ltd. — Investor Relations & Filings

Ticker · 298060 ISIN · KR7298060005 KO Manufacturing
Open in API
Filings indexed 418 across all filing types
Latest filing 2020-06-24 Major Shareholding Noti…
Country KR South Korea
Listing KO 298060

About SCM Lifescience Co., Ltd.

http://www.scmlifescience.com/en/

SCM Lifescience Co., Ltd. is a biotechnology company focused on developing high-purity, high-efficacy stem cell therapeutics for difficult-to-treat and incurable diseases. The company utilizes its proprietary source technology, the Subfractionation Culturing Method, to isolate and culture potent stem cells. Its pipeline consists of allogeneic stem cell therapies targeting immunological conditions, which are undergoing clinical trials. SCM Lifescience is also establishing mass production manufacturing processes using 3D bioreactor technology and expanding its research into induced pluripotent stem cells (iPSC) and tissue engineering. The company's business areas also include contract manufacturing (CMO), contract research, consulting, and cosmetics.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is a mandatory disclosure by major shareholders or insiders regarding their holdings and changes in ownership of a company's securities. In the provided taxonomy, this falls under 'Major Shareholding Notification' (MRQ) as it details the ownership status and changes in shareholding for a major shareholder (Korea Investment Future Growth Venture Fund No. 22).
2020-06-24 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed in South Korea. This type of filing is required under the Capital Markets Act when an entity or individual acquires a significant stake (typically 5% or more) in a listed company. It details the shareholding status, changes in ownership, and the purpose of the investment (in this case, 'simple investment'). This corresponds to the 'Major Shareholding Notification' category.
2020-06-24 Korean
증권발행실적보고서
Share Issue/Capital Change Classification · 100% confidence The document is a '증권발행실적보고서' (Report on the Results of Securities Issuance) filed with the Financial Supervisory Service (FSS) in South Korea. It details the final results of a public offering, including subscription and allocation status, shareholding changes, and the use of proceeds. This type of filing is a standard regulatory requirement following a capital raise (IPO or secondary offering) and falls under the category of share issuance and capital changes.
2020-06-11 Korean
[발행조건확정]증권신고서(지분증권)
Capital/Financing Update Classification · 95% confidence The document is a 'Securities Registration Statement' (증권신고서) filed with the Financial Services Commission in South Korea. It details the finalization of the public offering price (공모가액 확정) for SCM Lifescience Co., Ltd. and provides a comparison between the previous and updated offering terms. This is a regulatory filing related to capital raising and share issuance, which falls under the 'Regulatory Filings' category as it is a formal amendment to a registration statement.
2020-06-05 Korean
[기재정정]투자설명서
Capital/Financing Update Classification · 95% confidence The document is a 'Correction Report' (정정신고) for an 'Investment Prospectus' (투자설명서) filed by SCM Lifescience Co., Ltd. It details changes to the offering price and total offering amount following the finalization of the public offering price. In the context of financial filings, a prospectus or its amendment related to a public offering of shares is classified under 'Capital/Financing Update' (CAP) as it pertains to fundraising and capital structure changes.
2020-06-05 Korean
투자설명서
Capital/Financing Update Classification · 95% confidence The document is a '투자설명서' (Investment Prospectus) for SCM Lifescience Co., Ltd., detailing a public offering of 1,800,000 shares. It includes specific offering prices, subscription periods, payment dates, and detailed risk factors related to the company's business, clinical trials, and market conditions. In the context of financial filings, a prospectus for a public offering is classified as a Proxy Solicitation & Information Statement (PSI) or a regulatory filing related to capital raising. Given the specific options provided, 'PSI' (Proxy Solicitation & Information Statement) is the most appropriate category for a formal investment prospectus document used to solicit investor interest and provide required disclosures.
2020-06-03 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.